newsfilter
← Earnings
Earnings Releases·

Xencor — October 26, 2026 Earnings Summary

  • **Financial Position & Cash Runway:** The company reports a cash runway extending into 2029, with no specific revenue or earnings metrics disclosed for the period.
  • **XmAb819 Clinical Progress & Dosing:** XmAb819 demonstrated a 45.5% confirmed Objective Response Rate (cORR) at the 400 μg/kg dose in clear cell renal cell carcinoma (ccRCC), establishing this as the Recommended Phase 3 Dose (RP3D); full 400 μg/kg intravenous and subcutaneous data are expected in H1 2027, with a registration-enabling study initiation targeted for year-end 2027.
  • **Strategic Development & Regulatory Pathway:** Management plans to pursue an accelerated approval pathway for XmAb819 based on efficacy in post-immunotherapy/VEGFR-TKI subgroups and intends to design a global randomized control trial against tivozanib to support a Biologics License Application (BLA).
  • **Pipeline Expansion & Licensing:** The company is advancing Phase 3 programs for Xaluritamig (prostate/Ewing sarcoma) and ASP2138 (gastric/pancreatic cancer) while regaining development rights for plamotamab (RA) and new CD19-targeted antibodies, alongside ongoing Phase 2b updates for the IBD portfolio expected in H2 2027.
Company
XENCOR INC
Sector
Healthcare
Industry
Biotechnology